Comparison of chlorthalidone, propranolol and bopindolol in six-month treatment of arterial hypertension.
The aim of this study was to test the hypothesis that prolonged treatment of mild to moderate hypertension with low-dose thiazide diuretics or beta blockers does not induce any of the major untoward biochemical changes, such as hypertriglyceridemia, hypercholesterolemia, hyperuricemia and electrolyte imbalances. The effect of these drugs was analyzed in 100 outpatients (52 males and 48 females) aged 52.0 +/- 7.9 years with mild to moderate hypertension, in a prospective 6-month study. After an appropriate workup, the patients were randomized to either 25 mg chlorthalidone (40 patients), 120 mg propranolol (30 patients), or 2 mg per day bopindolol (30 patients). A significant reduction of approximately 10% in systolic and diastolic blood pressure was recorded in all the groups. At the end of the 6th month, in the chlorthalidone group triglycerides increased to 3.0 +/- 2.1 mmol/l from 2.8 +/- 1.6 mmol/l, while cholesterol after an initial increase to 6.6 +/- 1.6 from 6.4 +/- 1.6 mmol/l returned to the baseline level. Uricemia and serum potassium concentration decreased by 4%. The body weight was reduced to 83.8 +/- 13.4 kg from 86.1 +/- 13.4 kg. There was no change in serum glucose level. In the propranolol group, as expected, heart rate decreased by 20%, but there were no significant changes in glucose and potassium plasma concentration. Triglycerides did not change significantly, while cholesterol, after a small increase, returned to the initial levels. Similar results were obtained in the bopindolol group, apart from the triglycerides, which increased significantly (to 2.5 +/- 1.1 from 2.2 +/- 0.4 mmol/l), probably because of the lower baseline concentration. We conclude that in prolonged treatment, chlorthalidone, propranolol and bopindolol do not induce significant untoward biochemical changes that alone might increase cardiovascular risk.
Bagatin
J
J
Department of Medicine, University Hospital Split, Croatia.
Sardelić
S
S
Pivac
N
N
Polić
S
S
Ljutic
D
D
Rakic
D
D
Naranca
M
M
Bojić
L
L
Kovacić
Z
Z
Rumboldt
Z
Z
D000328:Adult; D000368:Aged; D001786:Blood Glucose / Q000187:drug effects; D001794:Blood Pressure / Q000187:drug effects; D002752:Chlorthalidone / Q000008:administration & dosage / Q000009:adverse effects*; D004311:Double-Blind Method; D005260:Female; D006801:Humans; D006949:Hyperlipidemias / Q000139:chemically induced*; D006973:Hypertension / Q000188:drug therapy* / Q000378:metabolism*; D007008:Hypokalemia / Q000139:chemically induced*; D008055:Lipids / Q000097:blood; D008297:Male; D008875:Middle Aged; D010869:Pindolol / Q000008:administration & dosage / Q000009:adverse effects / Q000031:analogs & derivatives*; D011433:Propranolol / Q000008:administration & dosage / Q000009:adverse effects*; D011446:Prospective Studies
D001786:Blood Glucose; D008055:Lipids; D011433:Propranolol; D010869:Pindolol; C036007:bopindolol; D002752:Chlorthalidone